CYP2C19 and clopidogrel outcomes in UK Biobank

CYP2C19 and clopidogrel outcomes in UK Biobank — Discovery

CYP2C19 and clopidogrel outcomes in UK Biobank - PubMed

The impact of CYP2C19 on clinical outcomes in clopidogrel-treated patients is substantial, highlighting the importance of incorporating ...

CYP2C19 and clopidogrel outcomes in UK Biobank — Discovery

This study utilizes the UK Biobank dataset, including 10 365 patients treated with clopidogrel, to offer the largest observational analysis of these ...

CYP2C19 and clopidogrel outcomes in UK Biobank - ResearchGate

Objective The impact of CYP2C19 genotype on clopidogrel outcomes is one of the most well established pharmacogenetic interactions, supported by robust ...

Analysis of CYP2C19 genetic variants with ischaemic events in UK ...

A substantial proportion of the UK population carry genetic variants that reduce metabolism of clopidogrel to its active form.

CYP2C19 Genotype Prevalence and Association With Recurrent ...

Cytochrome P450 family 2 subfamily C member 19 (CYP2C19) is a hepatic enzyme involved in the metabolism of clopidogrel from a prodrug to its active metabolite.

Pharmacogenetics at scale in real-world bioresources: CYP2C19 ...

Fingerprint. Dive into the research topics of 'Pharmacogenetics at scale in real-world bioresources: CYP2C19 and clopidogrel outcomes in UK Biobank'.

CYP2C19 Genotype Prevalence and Association With Recurrent ...

Pharmacokinetic studies have demonstrated lower active metabolite concentrations leading to decreased platelet response to clopidogrel in poor metabolizers (PMs) ...

CYP2C19 Genotype Prevalence and Association With Recurrent ...

The objective of this study was to assess prevalence of common CYP2C19 genotype polymorphisms in a British–South Asian population and correlate these with ...

(PDF) Analysis of CYP2C19 genetic variants with ischaemic events ...

Conclusions A substantial proportion of the UK population carry genetic variants that reduce metabolism of clopidogrel to its active form. In ...

CYP2C19 - PharmGKB

Pharmacogenetics at Scale: An Analysis of the UK Biobank. Clinical ... Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. The New ...

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and ...

Trinidad & Tobago has the highest prevalence of cardiovascular disease (CVD) in the Caribbean and clopidogrel is a ubiquitously used ...

From genes to drugs: CYP2C19 and pharmacogenetics in clinical ...

Poor metabolizer patients on Clopidogrel carrying CYP2C19 *3/*9 genotype may experience diminished antiplatelet effects, potentially increasing ...

Cardiovascular Pharmacogenetics: From Discovery of Genetic ...

Clopidogrel is the only CV drug with consistent PGx recommendation (i.e., “actionable”). This situation prompted us to dissect the steps from ...

Drug Response Pharmacogenetics for 200,000 UK Biobank ...

discover novel associations by investigating outcomes from normal clinical practice. ... clinical outcome using the UK Biobank primary care data.

Drug Response Pharmacogenetics for 200,000 UK Biobank ...

clinical outcome using the UK Biobank primary care data. We focus on two ... We also find CYP2C19 rapid metabolizers on clopidogrel have a.

Genetic variation in activating clopidogrel: longer-term outcomes in ...

CYP2C19 LoF (*2-*8, intermediate/poor metabolizers) carriers (n=2,144, 28.7%) were more likely to have an incident ischemic stroke whilst being ...

: Publications catalogue - UK Biobank

Pharmacogenetics at scale in real-world bioresources: CYP2C19 and clopidogrel outcomes in UK Biobank, Khaled F. Bedair (+4), 2023, Pharmacogenetics and ...

The impact of CYP2C19 genotype on phenoconversion ... - Frontiers

Conclusion: This study suggests that the differential outcome of CYP2C19-mediated DDIs between genotypes are primarily dictated by basal CYP2C19 ...

Pharmacogenetics of psychotropic drugs and genetic influences on ...

Chapter 2 uses UK Biobank data to consider the relationship between CYP2C19 and. CYP2D6 metabolic phenotype groups and several adverse drug ...

CYP2C19 loss‐of‐function alleles are not associated with higher ...

CYP2C19 dependent antidepressants are associated with increased GIB prevalence. GIB appeared independent from CYP2C19 metabolizer genotype in ...